Share on StockTwits

Aegerion Pharmaceuticals (NASDAQ: AEGR) was the recipient of a ratings changes during the seven days:

  • Aegerion Pharmaceuticals was downgraded by analysts at Citigroup Inc. from an “outperform” rating to a “market perform” rating.
  • Aegerion Pharmaceuticals had its price target lowered by analysts at Deutsche Bank from $115.00 to $70.00.
  • Aegerion Pharmaceuticals had its price target lowered by analysts at Jefferies Group from $80.00 to $61.00.
  • Aegerion Pharmaceuticals had its price target lowered by analysts at FBR Capital Markets from $111.00 to $107.00. They now have an “outperform” rating on the stock.
  • Aegerion Pharmaceuticals was downgraded by analysts at Cowen and Company from an “outperform” rating to a “market perform” rating. They now have a $36.00 price target on the stock, down previously from $85.00.

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) opened at 32.62 on Monday. Aegerion Pharmaceuticals, Inc. has a one year low of $30.43 and a one year high of $101.00. The stock has a 50-day moving average of $43.17 and a 200-day moving average of $60.69. The company’s market cap is $959.4 million.

Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.